Literature DB >> 3501355

Enzyme immunoassays for the detection of IgG and IgM anti-dsDNA antibodies: clinical significance and specificity.

A G Tzioufas1, M N Manoussakis, A A Drosos, G Silis, A E Gharavi, H M Moutsopoulos.   

Abstract

A solid phase Enzyme-Linked Immunosorbent Assay (ELISA) was developed for the measurement of IgG and IgM antibodies to double-stranded DNA (anti-dsDNA). This method is sensitive, specific, relatively simple and suitable for routine use. Thus, we evaluated sera from 224 Greek patients with the following autoimmune rheumatic diseases: 54 patients with classical rheumatoid arthritis (RA), 50 patients with primary Sjögren's syndrome (SS), 41 patients with systemic lupus erythematosus (SLE), 30 patients with scleroderma, 20 patients with idiopathic Raynaud's phenomenon (IRP) and 29 patients with juvenile rheumatoid arthritis (JRA). Sera from 119 age- and sex-matched healthy blood donors were tested as normal controls. The presence of both IgG and IgM anti-dsDNA highly correlated with SLE. However, IgM anti-dsDNA levels were significantly lower. Serum complement C3 and C4 levels correlated negatively with anti-dsDNA levels in the SLE group. Finally, in sequential sera from five SLE patients, the anti-dsDNA activity proved to be a relatively sensitive marker of SLE activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501355

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

1.  Determination of anti-ds-DNA antibodies by three different methods: comparison of sensitivity, specificity and correlation with lupus activity index (LAI).

Authors:  A G Tzioufas; C Terzoglou; E D Stavropoulos; S Athanasiadou; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1990-06       Impact factor: 2.980

2.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Quantification of cross-reactive idiotype-positive rheumatoid factor produced in autoimmune rheumatic diseases. An indicator of clonality and B cell proliferative mechanisms.

Authors:  F Shokri; R A Mageed; G D Kitas; P Katsikis; H M Moutsopoulos; R Jefferis
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

4.  Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.

Authors:  I Martin-Suarez; D D'Cruz; M Mansoor; A P Fernandes; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1997-08       Impact factor: 19.103

5.  Cross-recognition between histones and La/SSB may account for anti-DNA reactivity in SLE patients.

Authors:  E Touloupi; J G Routsias; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease.

Authors:  A G Tzioufas; N G Tzortzakis; E Panou-Pomonis; K A Boki; M Sakarellos-Daitsiotis; C Sakarellos; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

7.  Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset.

Authors:  A Siamopoulou-Mavridou; M N Manoussakis; A K Mavridis; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

8.  Unusual eye manifestations in systemic lupus erythematosus patients.

Authors:  A A Drosos; C A Petris; G M Petroutsos; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

9.  Anti-5S RNA/protein (RNP) antibody levels correlate with disease activity in a patient with systemic lupus erythematosus (SLE) nephritis.

Authors:  A Guialis; M Patrinou-Georgoula; N Tsifetaki; V Aidinis; C E Sekeris; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

10.  Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis.

Authors:  G N Dalekos; M N Manoussakis; A C Goussia; E V Tsianos; H M Moutsopoulos
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.